←Back to Expert Scholars
Translational Medicine / 转化医学KRAS G12C Later-Line Therapy
James Fell
PhD
🏢Revolution Medicines🌐USA
Vice President, Drug Discovery
35
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
James Fell leads drug discovery at Revolution Medicines developing next-generation RAS(ON) inhibitors that target active-state KRAS. His work addresses the limitation of current G12C inhibitors that only bind the inactive GDP-bound state. These novel agents may provide improved later-line options for KRAS-mutant cancers.
Share:
🧪Research Fields 研究领域
KRAS G12C
RAS(ON) inhibitors
Drug discovery
Medicinal chemistry
Next-generation KRAS agents
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 James Fell 的研究动态
Follow James Fell's research updates
留下邮箱，当我们发布与 James Fell（Revolution Medicines）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment